Recognition of adult T-cell leukemia/lymphoma cells by CD4+ helper T lymphocytes specific for human T-cell leukemia virus type I envelope protein

Clinical Cancer Research

Volumn 10, Issue 20, 2004, Pages 7053-7062

  Kobayashi, Hiroya ^a   Nagato, Toshihiro ^a   Yanai, Mitsuru ^a   Oikawa, Kensuke ^a   Sato, Keisuke ^a   Kimura, Shoji ^a   Tateno, Masatoshi ^a   Omiya, Ryusuke ^b   Celis, Esteban ^b  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; HLA DQ ANTIGEN; HLA DQW6 ANTIGEN; HLA DR ANTIGEN; HLA DR15 ANTIGEN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS ENVELOPE PROTEIN[196-210]; VIRUS ENVELOPE PROTEIN[317-331]; VIRUS ENVELOPE PROTEIN[384-398];

ALGORITHM; AMINO ACID SEQUENCE; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; DRUG RESISTANCE; DRUG SYNTHESIS; HELPER CELL; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNE RESPONSE; IN VITRO STUDY; LEUKEMIA CELL; LYMPHOMA CELL; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN FUNCTION; T CELL LEUKEMIA; T CELL LYMPHOMA; TUMOR IMMUNITY; VIRUS PATHOGENESIS;

ALGORITHMS; CD4-POSITIVE T-LYMPHOCYTES; EPITOPES; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; IMMUNOTHERAPY; LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED; TUMOR CELLS, CULTURED; VIRAL ENVELOPE PROTEINS;

EID: 6044233329     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0897     Document Type: Article

References (38)

1. Poiesz BJ, Ruscetti FW, Gazdar AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980;77:7415-9.
2. Uchiyama T. Human T-cell leukemia virus type I (HTLV-I) and human disease. Annu Rev Immunol 1997;15:15-37.
3. Kannagi M, Sugamura K, Kinoshita K, Uchino H, Hinuma Y. Specific cytolysis of fresh tumor cells by an autologous killer T cell line derived from an adult T-cell leukemia/lymphoma patient. J Immunol 1984;133:1037-41.
4. Jacobson S, Shida H, McFarlin DE, Fauci AS, Koenig S. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature (Lond.) 1990;348;245-8.
5. Parker CE, Daenke S, Nightingale S, Bangham CR. Activated, HTLV-I-specific cytotoxic T lymphocytes are found in healthy seropositive as well as in patients with tropical spastic paraparesis. Virology 1992;188:632-6.
6. Kannagi M, Matsushita S, Harada S. Expression of the target antigen for cytotoxic T lymphocytes on adult T-cell leukemia cells. Int J Cancer 1993;54:582-8.
7. Manca F, LiPira G, Fenoglio D, et al. Recognition of human T-leukemia virus (HTLV-I) envelope by human CD4+ T-cell lines from HTLV-I seronegative individuals. Blood 1995;85:1547-54.
8. + T cells: immunodominance hierarchy and preferential infection with HTLV-I. J Immunol 2004;172:1735-43.
9. Baba E, Nakamura M, Ohkuma K, et al. A peptide-based human T-cell leukemia virus type I vaccine containing T- and B-cell epitopes that induces high titers neutralizing antibodies. J Immunol 1995;154:399-412.
10. Lairmore MD, DiGeorge AM, Conrad SF, Trevino AV, Lal RB, Kaumaya PTP. Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction. J Virol 1995;69:6077-89.
11. Chesnut RW, Sette A, Celis E, et al. Design and testing of peptide-based cytotoxic T-cell-mediated immunotherapies to treat infectious diseases and cancer. In: Powell MF, Newman MJ, editors. Vaccine design. New York: Plenum Press; 1995. P. 847-73.
12. Melief CJ, Offringa R, Toes RE, Kast WM. Peptide-based cancer vaccines. Curr Opin Immunol 1996;8:651-7.
13. Marchand M, Weynants P, Rankin E, et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995;63:883-5.
14. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-7.
15. Kannagi M, Shida H, Igarashi H, et al. Target epitope in the Tax protein of human T-cell leukemia virus type I recognized by class I major histocompatibility complex-restricted cytotoxic T cells. J Virol 1992;66:2928-33.
16. Parker CE, Nightingale S, Taylor GP, et al. Circulating anti-Tax cytotoxic T lymphocytes from human T-cell leukemia virus type I-infected people, with and without tropical spastic paraparesis, recognized multiple epitopes simultaneously. J Virol 1994;68:2860-8.
17. Bieganowska K, Hollsberg P, Buckle GJ, et al. Direct analysis of viral-specific CD8+ T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T-cell lymphotropic virus-associated myelopathy. J Immunol 1999;162:1765-71.
18. Giuntoli RL 2nd, Lu J, Kobayashi H, Kennedy R, Celis E. Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. Clin Cancer Res 2002;8:922-31.
19. Nikiforow S, Bottomly K, Miller GCD. 4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation. J Virol 2001;75:3740-52.
20. Kobayashi H, Lu J, Celis E. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen. Cancer Res 2001;61:7577-84.
21. Omiya R, Buteau S, Kobayashi H, Paya CV, Celis E. Inhibition of EBV-induced lymphoproliferation by CD4+ T cells specific for an MHC class II promiscuous epitope. J Immunol 2002;169:2172-9.
22. Zang Y, Chaux P, Stroobant V, et al. A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. J Immunol 2003;171:219-25.
23. Miyoshi I, Kubonishi I, Yoshimoto S, et al. Type C virus particles in a cord T-cell lines derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature (Lond.) 1981;294:770-1.
24. Southwood S, Sidney I, Kondo A, et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998;160:3363-73.
25. Kobayashi H, Omiya R, Ruiz M, et al. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin Cancer Res 2002;8:3219-25.
26. Kobayashi H, Song Y, Hoon DS, Appella E, Cells E. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res 2001;61:4773-8.
27. Kobayashi H, Wood M, Song Y, Appella E, Celis E. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res 2000;60:5228-36.
28. Kobayashi H, Omiya R, Sodey B, et al. Identification of naturally processed helper T-cell epitopes from prostate-specific membrane antigen using peptide-based in vitro stimulation. Clin Cancer Res 2003;9:5386-93.
29. Yamano Y, Kitze B, Yashiki S, et al. Preferential recognition of synthetic peptides from HTLV-I gp21 envelope protein by HLA-DRB1 alleles associated with HAM/TSP (HTLV-I-associated myelopathy/tropical spastic paraparesis). J Neuroimmunol 1997;76:50-60.
30. Baba E, Nakamura M, Tanaka Y, et al. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type I (HTLV-1) identified by human monoclonal antibodies: a basis for the design of an HTLV-1 peptide vaccine. J Immunol 1993;151:1013-24.
31. Palker TJ, Riggs ER, Spragion DE, et al. Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins. J Virol 1992;66:5879-89.
32. Palker TJ, Tanner M, Screace R, Streuen R, Clark M, Haynes B. Mapping of immunogenic regions of human T-cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with Env-coded synthetic peptides and a monoclonal antibody to gp46. J Immunol 1989;142:971-8.
33. Jacobson S, Reuben JS, Streilein RD, Palker TJ. Induction of CD4+, human T lymphotropic virus type-1-specific cytotoxic T lymphocytes from patients with HAM/TSP. J Immunol 1991;146:1155-62.
34. Kitze B, Usuku K, Yamano Y, et al. Human CD4+ T lymphocytes recognize a highly conserved epitope of human T lymphotropic virus type 1 (HTLV-1) env gp21 restricted by HLA-DRB1*0101. Clin Exp Immunol 1998;111:278-85.
35. Chicz RM, Urban RG, Gorga JC, Vignali DAA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993;178:24-47.
36. Hanabuchi S, Ohashi T, Koya Y, et al. Regression of human T-cell leukemia virus type I (HTLV-I)-associated lymphomas in rat model: peptide-induced T-cell immunity. J Natl Cancer Inst (Bethesda) 2001;93:1775-83.
37. Vergelli M, Hemmer B, Muraro PA, et al. Human autoreactive CD4+ T-cell clones use perform- or Fas/Fas ligand-mediated pathways for target cell lysis. J Immunol 1997;158:2756-61.
38. Pique C, Connan F, Levilain JP, Choppin J, Dokhelar MC. Among all human T-cell leukemia virus type 1 proteins, Tax, polymerase and envelope proteins are predicted as preferential targets for the HLA-A2-restricted cytotoxic T-cell response. J Virol 1996;70:4919-26.